Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04527354
Recruitment Status : Active, not recruiting
First Posted : August 26, 2020
Last Update Posted : November 18, 2020
Sponsor:
Information provided by (Responsible Party):
PHARMENTERPRISES LLC

Brief Summary:

The innovative drug Treamid is planned for use in the rehabilitation of patients after COVID-19 pneumonia in a pilot, multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to assess the efficacy and safety of Treamid, tablets, 50 mg in patients with fibrotic changes in the lungs after COVID-19 pneumonia during a 28-day treatment.

The primary objective of the study is to demonstrate the efficacy of Treamid tablet, 50 mg in change in forced vital capacity (FVC) and/or diffusing capacity of lung for carbon monoxide (DLCO) at Week 4.

The secondary objective of the study is to evaluate the safety of Treamid tablet, 50 mg and pharmacokinetics (PK).


Condition or disease Intervention/treatment Phase
SARS-CoV-2 Infection Fibrosis Lung Drug: Treamid Drug: Placebo Phase 2

Detailed Description:

12-15 Russian centers are planned for participation in this pilot study. The study consists of three periods: screening (2 weeks), treatment period (4 weeks) and follow-up period (2 weeks after completion of treatment with Treamid / Placebo). The duration of participation in the study for each patient is no more than 8 weeks.

60 patients with fibrotic changes in the lungs after COVID-19 pneumonia are planned to be randomized. All patients will undergo a qualitative determination of coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by polymerase chain reaction (PCR). Patients will be evaluated using the Modified British Medical Research Council (mMRC) Dyspnea Scale, chest computed tomography (CT), spirometry and body plethysmography with determination of DLCO. This examination should be conducted as close as possible to the expected randomization date (no earlier than 5 days before). All eligible patients will be randomized into 2 groups in a 1:1 ratio: Treamid 50 mg daily (30 patients); Placebo (30 patients).

During the treatment period (4 weeks), patients will receive 1 tablet Treamid / Placebo once a day. Patients will be advised to continue the standard program of medical rehabilitation under day inpatient or outpatient conditions (stage 3 according to the Interim Guidelines for Medical Rehabilitation after New Coronavirus Infection (COVID-19), 2020.

Patients will visit the study center once a week. At the Week 1, Week 2 and Week 3 visits, Adverse events (AEs) and concomitant therapy, investigational drug registration, body weight, vital signs and Oxygen saturation (SpO2) scores, mMRC dyspnea score and spirometry will be recorded.

During the Week 2 visit, physical examination, electrocardiography (ECG), complete blood count (CBC) and biochemical blood test, PK study, common urine analysis, bodyplethysmography with DLCO will also be conducted. Patients will complete the KBILD questionnaire. Also, the patients will undergo a 6-minute walk test to measure the distance the patient walks for 6 minutes and evaluate using the Borg Scale. At the Week 4 visit (the end of the therapy), registration of AEs and concomitant therapy, physical examination, measurement of height, body weight, vital signs and SpO2, ECG, CBC and biochemical blood tests, PK study and common urine analysis will be conducted. Patients will be evaluated using the mMRC Dyspnea Scale, chest CT, spirometry and body plethysmography with determination of DLCO. Patients will complete the King's Brief Interstitial Lung Disease Questionnaire (KBILD) followed by a 6-minute walk test to measure the distance the patient walks for 6 minutes and evaluate using the Borg Scale.

Patient follow-up will continue for another 2 weeks. At the Week 6 visit, registration of AEs and concomitant therapy, physical examination, measurement of height, body weight, vital signs and SpO2, ECG, mMRC dyspnea score, CBC and biochemical blood tests, and common urine analysis will be conducted.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: A blind will be performed by using Placebo equivalent to Treamid tablets without active substance and the corresponding labeling of the study drug.
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia
Actual Study Start Date : September 8, 2020
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treamid 50 mg
1 tablet of Treamid 50 mg once a day during 4 weeks of treatment period.
Drug: Treamid
Participants will receive Treamid 50 mg once a day during 4 weeks

Placebo Comparator: Placebo
1 tablet of Placebo once a day during 4 weeks of treatment period
Drug: Placebo
Participants will receive Placebo once a day during 4 weeks




Primary Outcome Measures :
  1. Rate of clinically significant change in FVC and/or DLCO at Week 4 relative to the baseline value [ Time Frame: Day 1- Day 28 ]
    Clinically significant changes include a relative ≥ 10% increase in FVC or a relative increase in FVC within the range from ≥ 5% to <10% and a relative ≥ 15% in DLCO


Secondary Outcome Measures :
  1. Change in distance covered for 6 minutes (6MWD) at Weeks 2 and 4 from the baseline value (based on 6-minute walk test) [ Time Frame: Day 1- Day 28 ]
  2. Change in the score of the Borg scale at Weeks 2 and 4 from the baseline value (based on the 6-minute walk test) [ Time Frame: Day 1- Day 28 ]
  3. Change in forced expiratory volume for the first second (FEV1) according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values [ Time Frame: Day 1- Day 28 ]
  4. Change in FVC according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values [ Time Frame: Day 1- Day 28 ]
  5. Change in FEV1/FVC according to spirometry data at Weeks 1, 2, 3 and 4 relative to the baseline values [ Time Frame: Day 1- Day 28 ]
  6. Change in DLCO according to bodyplethysmography at Week 2 and Week 4 relative to baseline values [ Time Frame: Day 1- Day 28 ]
  7. Change in Total Lung Capacity (TLC) according to bodyplethysmography at Week 2 and Week 4 relative to baseline values [ Time Frame: Day 1- Day 28 ]
  8. Change in Functional Residual Capacity (FRC) according to bodyplethysmography at Week 2 and Week 4 relative to baseline values [ Time Frame: Day 1- Day 28 ]
  9. The rate of reduction in the lung damage degree based on the computed tomography (CT) at Week 4 relative to the baseline value [ Time Frame: Day 1- Day 28 ]
    Classification of lung damage includes the following stages: CT-0 (norm), CT-1 (< 25% of lung damage), CT-2 (25-50% of lung damage), CT-3 (50-75% of lung damage), CT-4 (> 75% of lung damage)

  10. Change in mMRC Dyspnea Score in Week 1, Week 2, Week 3, and Week 4 from the baseline value [ Time Frame: Day 1- Day 28 ]
  11. Change in the overall score of the KBILD Questionnaire at Week 2 and Week 4 relative to the baseline value [ Time Frame: Day 1- Day 28 ]

Other Outcome Measures:
  1. The rate of adverse events (AEs) [ Time Frame: Day 1- Day 28 ]
  2. The rate of serious adverse events (SAEs) [ Time Frame: Day 1- Day 28 ]
  3. Residual concentration Ctrough of the active substance of Treamid [ Time Frame: Day 1- Day 28 ]
    Blood sampling for the PK study of the parameter Сtrough will be performed for all patients prior to administration of the Treamid / Placebo at Week 0, Week 2, and Week 4 visits.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed patient explanation sheet and informed consent for participation in the study.
  2. Men and women at the age from 18 through 75 years old.
  3. Fibrous changes in the lungs after COVID-19 pneumonia:

    1. COVID-19 diagnosis in the past medical history confirmed by positive qualitative analysis of SARS-CoV-2 RNA by PCR method;
    2. The first symptoms of COVID-19 appear no earlier than 2 months before the screening visit;
    3. Fibrous changes in the lungs characteristic for COVID-19 confirmed by the chest CT scan at screening visit.
  4. Negative COVID-19 screening test (confirmed).
  5. Severity grade 2 (moderate) or 3 (severe) according to the mMRC Dyspnea Scale at the screening and randomization visits.
  6. Decreased lung function FVC and/or DLCO <80% of the predicted value at the screening visit.
  7. The patient's consent to use adequate contraception methods during the entire study and within 3 months after its completion. The adequate contraception methods include the use of the following:

    • oral or transdermal contraceptives;
    • condom or diaphragm (barrier method) with spermicide;
    • intrauterine device.

Exclusion Criteria:

  1. Pregnant or breastfeeding women, or women planning pregnancy during the clinical study; women with childbearing potential (including those who have not been sterilized by surgery and in the postmenopausal period for less than 2 years) who do not use adequate contraception methods.
  2. The use of invasive artificial lung ventilation (iALV), plasma transfusion (including plasma of convalescents) and other blood components during therapy against COVID-19.
  3. Chronic airway disease in the past medical history, including idiopathic pulmonary fibrosis (IPF), bronchial asthma, chronic obstructive pulmonary disease (COPD), or pulmonary hypertension, diagnosed before COVID-19.
  4. Significant cardiovascular diseases at present time or during 6 months prior to the screening, including: chronic heart failure class III or IV (according to the New York Heart Association classification), clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction, heart and coronary surgery, significant heart valves disease, uncontrolled hypertension with systolic blood pressure> 180 mm Hg and diastolic blood pressure> 110 mm Hg, thromboembolia of the pulmonary artery or deep vein thrombosis
  5. Nephrotic syndrome, moderate to severe chronic renal failure, or significant kidney disease with a glomerular filtration rate (GFR) <60 ml/min at the screening visit.
  6. Cirrhosis of the liver in the past medical history; increase in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) by 3 or more times from the upper normal level (UNL) at the screening visit; an increase in the total bilirubin level by 2 or more times from UNL at the screening visit.
  7. Hemoglobin level <90 g/L at the screening visit.
  8. Severe diseases of the central nervous system, including seizures or conditions in the past medical history that can cause their development; stroke or transient ischemic attack within 6 months prior to the screening visit; traumatic brain injury or loss of consciousness within 6 months prior to the screening visit; a brain tumor.
  9. Signs of severe uncontrolled intercurrent disease, such as disorders of the nervous system, kidney, liver, endocrine system and gastrointestinal tract, which, in the opinion of the Investigator, could interfere with the patient's participation in the study.
  10. Malignant neoplasms requiring chemotherapy treatment within 6 months prior to the screening visit.
  11. HIV infection in the past-medical history.
  12. Prostate cancer or benign prostatic hyperplasia (BPH) with residual urine volume of more than 100 ml in the past medical history of men.
  13. Hypersensitivity or intolerance to any component of the investigated drug.
  14. Participation in other clinical studies within 2 months prior to the screening visit.
  15. Administration of the following medications: bronchodilators, anticholinergics, corticosteroids, cytostatics, colchicine, cyclosporin A, interferon-γ-1b, bosentan, macitentan, etanercept, sildenafil, imatinib, n-acetylcysteine, warfarin, ambrisentan, nintedanib, pirfenidone 1 month prior to the screening visit.
  16. Inability to read or write; unwillingness to understand and follow the procedures of the study protocol; noncompliance with the drugs administration or procedures schedule, which according to the researchers may affect the study results or the patient safety and prevent the further participation of the patient in the study; any other associated medical or serious mental conditions that make the patient inadequate for participation in the clinical study and restrict the validity of informed consent or may affect the patient's ability to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04527354


Locations
Layout table for location information
Russian Federation
State Federal-Funded Educational Institution of Higher Professional Training "Kazan State Medical University" of the Ministry of Health Care and Social Development of the Russian Federation
Kazan, Russian Federation, 420012
Federal State-Funded Research Institution "Research Institute of Complex Cardiovascular Diseases"
Kemerovo, Russian Federation, 650002
State Federal-Funded Educational Institution of Higher Professional Training "Kemerovo State Medical University" of the Ministry of Healthcare of the Russian Federation
Kemerovo, Russian Federation, 650029
SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines
Moscow, Russian Federation, 119435
State Federal-Funded Institution of Health Care of the city of Moscow "City Clinical Hospital named after M.E. Zhadkevich of the Moscow City Health Department"
Moscow, Russian Federation, 121374
Moscow State Medical-Dentist University n.a. A.I. Evdokimov on basis of SMHI "City Hospital № 62", branch 5
Moscow, Russian Federation, 121552
State Budgetary Institution of Healthcare "Leningrad region Clinical Hospital"
Saint Petersburg, Russian Federation, 194291
State Federal-Funded Educational Institution of Higher Professional Training "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Healthcare of the Russian Federation
Saratov, Russian Federation, 410012
State Federal-Funded Institution of Health Care "Republican Clinical Hospital named after G.G. Kuvatov"
Ufa, Russian Federation, 450005
State Federal-Funded Educational Institution of Higher Professional Training "Bashkir State Medical University" of the Ministry of Healthcare of the Russian Federation
Ufa, Russian Federation, 450083
State Federal-Funded Educational Institution of Higher Professional Training "Volgograd State Medical University" of the Ministry of Healthcare of the Russian Federation
Volgograd, Russian Federation, 400131
State autonomous healthcare institution of Yaroslavl Region "Сlinical hospital for emergency medical care n. a. N.V. Solovyov"
Yaroslavl, Russian Federation, 150003
Sponsors and Collaborators
PHARMENTERPRISES LLC
Layout table for additonal information
Responsible Party: PHARMENTERPRISES LLC
ClinicalTrials.gov Identifier: NCT04527354    
Other Study ID Numbers: COVID-TRE-03
First Posted: August 26, 2020    Key Record Dates
Last Update Posted: November 18, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by PHARMENTERPRISES LLC:
COVID-19
Coronavirus
Rehabilitation
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections